What's new in the treatment of portopulmonary hypertension?

Hilary M. Dubrock, Richard N. Channick, Michael Joseph Krowka

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Portopulmonary hypertension (POPH) is a complication of portal hypertension characterized by pulmonary vasoconstriction and vascular remodeling that can lead to right heart failure and death. Differentiation of POPH from other causes of pulmonary hypertension, such as volume overload or a hyperdynamic high flow state, is critical because a diagnosis of POPH has significant implications for liver transplant risk stratification, Model for End Stage Liver Disease exception points, and the use of pulmonary arterial hypertension-(PAH) specific therapy. Currently, there are 12 approved medications for the treatment of PAH in the US, and three of these were approved in 2013. This review will discuss the diagnosis, evaluation and management of POPH and the role of recently approved PAH therapies in the treatment of POPH.

Original languageEnglish (US)
Pages (from-to)983-992
Number of pages10
JournalExpert Review of Gastroenterology and Hepatology
Volume9
Issue number7
DOIs
StatePublished - Sep 1 2015

Fingerprint

Hypertension
Pulmonary Hypertension
End Stage Liver Disease
Portal Hypertension
Vasoconstriction
Heart Failure
Transplants
Lung
Liver
Therapeutics

Keywords

  • macitentan
  • portopulmonary hypertension
  • pulmonary arterial hypertension
  • riociguat
  • treatment
  • treprostinil

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

What's new in the treatment of portopulmonary hypertension? / Dubrock, Hilary M.; Channick, Richard N.; Krowka, Michael Joseph.

In: Expert Review of Gastroenterology and Hepatology, Vol. 9, No. 7, 01.09.2015, p. 983-992.

Research output: Contribution to journalArticle

@article{3f86438fdd064f76a1bfa798463a4275,
title = "What's new in the treatment of portopulmonary hypertension?",
abstract = "Portopulmonary hypertension (POPH) is a complication of portal hypertension characterized by pulmonary vasoconstriction and vascular remodeling that can lead to right heart failure and death. Differentiation of POPH from other causes of pulmonary hypertension, such as volume overload or a hyperdynamic high flow state, is critical because a diagnosis of POPH has significant implications for liver transplant risk stratification, Model for End Stage Liver Disease exception points, and the use of pulmonary arterial hypertension-(PAH) specific therapy. Currently, there are 12 approved medications for the treatment of PAH in the US, and three of these were approved in 2013. This review will discuss the diagnosis, evaluation and management of POPH and the role of recently approved PAH therapies in the treatment of POPH.",
keywords = "macitentan, portopulmonary hypertension, pulmonary arterial hypertension, riociguat, treatment, treprostinil",
author = "Dubrock, {Hilary M.} and Channick, {Richard N.} and Krowka, {Michael Joseph}",
year = "2015",
month = "9",
day = "1",
doi = "10.1586/17474124.2015.1035647",
language = "English (US)",
volume = "9",
pages = "983--992",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "7",

}

TY - JOUR

T1 - What's new in the treatment of portopulmonary hypertension?

AU - Dubrock, Hilary M.

AU - Channick, Richard N.

AU - Krowka, Michael Joseph

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Portopulmonary hypertension (POPH) is a complication of portal hypertension characterized by pulmonary vasoconstriction and vascular remodeling that can lead to right heart failure and death. Differentiation of POPH from other causes of pulmonary hypertension, such as volume overload or a hyperdynamic high flow state, is critical because a diagnosis of POPH has significant implications for liver transplant risk stratification, Model for End Stage Liver Disease exception points, and the use of pulmonary arterial hypertension-(PAH) specific therapy. Currently, there are 12 approved medications for the treatment of PAH in the US, and three of these were approved in 2013. This review will discuss the diagnosis, evaluation and management of POPH and the role of recently approved PAH therapies in the treatment of POPH.

AB - Portopulmonary hypertension (POPH) is a complication of portal hypertension characterized by pulmonary vasoconstriction and vascular remodeling that can lead to right heart failure and death. Differentiation of POPH from other causes of pulmonary hypertension, such as volume overload or a hyperdynamic high flow state, is critical because a diagnosis of POPH has significant implications for liver transplant risk stratification, Model for End Stage Liver Disease exception points, and the use of pulmonary arterial hypertension-(PAH) specific therapy. Currently, there are 12 approved medications for the treatment of PAH in the US, and three of these were approved in 2013. This review will discuss the diagnosis, evaluation and management of POPH and the role of recently approved PAH therapies in the treatment of POPH.

KW - macitentan

KW - portopulmonary hypertension

KW - pulmonary arterial hypertension

KW - riociguat

KW - treatment

KW - treprostinil

UR - http://www.scopus.com/inward/record.url?scp=84931824664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931824664&partnerID=8YFLogxK

U2 - 10.1586/17474124.2015.1035647

DO - 10.1586/17474124.2015.1035647

M3 - Article

C2 - 25882070

AN - SCOPUS:84931824664

VL - 9

SP - 983

EP - 992

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 7

ER -